➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Dow
AstraZeneca
McKesson
Johnson and Johnson

Last Updated: November 30, 2020

DrugPatentWatch Database Preview

Claims for Patent: 8,222,244

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,222,244
Title:Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity
Abstract: The present invention relates to the use of staurosporines derivatives for the preparation of a drug for the treatment of diseases involving deregulated FLT3 receptor tyrosine kinase activity, especially for the curative and/or prophylactic treatment of leukemias and myelodysplastic syndromes, and to a method of treating diseases involving deregulated FLT3 receptor tyrosine kinase activity.
Inventor(s): Griffin; James D (Brookline, MA), Manley; Paul W (Arlesheim, CH)
Assignee: Novartis AG (Basel, CH) Dana-Farber Cancer Institute Inc. (Boston, MA)
Application Number:13/109,511
Patent Claims: 1. A method for treating a mammal suffering from acute myeloid leukemia comprising administering to a mammal in need of such treatment a therapeutically effective amount of N-[(9S,10R,11R,13R)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9- ,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-Im]pyrrolo[3,4-j][1,7]benzodiaz- onin-11-yl]-N-methylbenzamide of the formula (VII): ##STR00007## or a salt thereof; wherein the acute myeloid leukemia is characterized by deregulated FLT3 receptor tyrosine kinase activity.

2. A method according to claim 1, wherein the therapeutically effective amount of the compound of formula VII is administered to a mammal subject 7 to 4 times a week or about 100% to about 50% of the days during a period of from one to six weeks, followed by a period of one to three weeks, wherein the agent is not administered and this cycle being repeated for from 1 to several cycles.

3. A method according to claim 1, wherein 225 mg of the compound of formula VII is administered daily.

4. A method according to claim 1, wherein the compound of formula VII is administered orally.

5. A method according to claim 4, wherein the compound of formula VII is administered as a microemulsion, soft gel or solid dispersion.

6. A method according to claim 5, wherein the compound of formula VII is administered as a microemulsion.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Johnson and Johnson
Merck
McKesson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.